One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

Andrew Craig Miller net worth and biography

Andrew Miller Biography and Net Worth

COO of Karuna Therapeutics

Dr. Miller is a Founder and the Chief Operating Officer of Karuna Therapeutics. Dr. Miller is the lead inventor of Karuna’s KarXT platform and served as CEO of Karuna from 2016-2018. He served as a member of our board of directors from April 2012 to March 2019. From August 2008 to July 2016, Dr. Miller held several positions at PureTech Health plc, last serving as a Vice President, Venture Partner, in such capacity served as Chief Operating Officer of Tal Medical and the acting Chief Operating Officer of Entrega, Inc. He is currently a member of the board of directors of Entrega, Inc.

Dr. Miller received a B.S. in chemical engineering from the University of Illinois with highest honors. He completed his doctoral work in chemical engineering at the Massachusetts Institute of Technology and received the MIT Presidential fellow and National Defense Science and Engineering Graduate fellowship awards. In 2016, Dr. Miller was named one of the top 40 innovators under 40 by MedTech Boston.

What is Andrew Craig Miller's net worth?: The estimated net worth of Andrew Craig Miller is at least $8.05 million as of April 20th, 2023. Dr. Miller owns 24,400 shares of Karuna Therapeutics stock worth more than $8,047,852 as of April 19th. This net worth evaluation does not reflect any other assets that Dr. Miller may own. Additionally, Dr. Miller receives an annual salary of $835,400.00 as COO at Karuna Therapeutics. Learn More about Andrew Craig Miller's net worth.
How old is Andrew Craig Miller?: Dr. Miller is currently 42 years old. There are 3 older executives and no younger executives at Karuna Therapeutics. Learn More on Andrew Craig Miller's age.
What is Andrew Craig Miller's salary?: As the COO of Karuna Therapeutics, Inc., Dr. Miller earns $835,400.00 per year. Learn More on Andrew Craig Miller's salary.
How do I contact Andrew Craig Miller?: The corporate mailing address for Dr. Miller and other Karuna Therapeutics executives is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. Karuna Therapeutics can also be reached via phone at (857) 449-2244 and via email at [email protected]. Learn More on Andrew Craig Miller's contact information.
Has Andrew Craig Miller been buying or selling shares of Karuna Therapeutics?: Andrew Craig Miller has not been actively trading shares of Karuna Therapeutics over the course of the past ninety days. Most recently, Andrew Craig Miller sold 15,000 shares of the business's stock in a transaction on Thursday, April 20th. The shares were sold at an average price of $200.13, for a transaction totalling $3,001,950.00. Following the completion of the sale, the chief operating officer now directly owns 24,400 shares of the company's stock, valued at $4,883,172. Learn More on Andrew Craig Miller's trading history.
Who are Karuna Therapeutics' active insiders?: Karuna Therapeutics' insider roster includes Stephen Brannan (Insider), James Healy (Director), Troy Ignelzi (CFO), Jeffrey Jonas (Director), Andrew Miller (COO), Laurie Olson (Director), Atul Pande (Director), Steven Paul (CEO), and Heather Preston (Director). Learn More on Karuna Therapeutics' active insiders.
Are insiders buying or selling shares of Karuna Therapeutics?: In the last twelve months, insiders at the sold shares 13 times. They sold a total of 104,119 shares worth more than $23,414,081.47. The most recent insider tranaction occured on March, 8th when insider Stephen K Brannan sold 5,000 shares worth more than $1,591,700.00. Insiders at Karuna Therapeutics own 13.2% of the company. Learn More about insider trades at Karuna Therapeutics.
Information on this page was last updated on 3/8/2024.

Andrew Craig Miller Insider Trading History at Karuna Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/20/2023	Sell	15,000	$200.13	$3,001,950.00	24,400
4/18/2023	Sell	30,000	$200.16	$6,004,800.00	30,900
12/1/2022	Sell	15,000	$228.30	$3,424,500.00	11,250
11/1/2022	Sell	15,000	$225.08	$3,376,200.00	38,500
9/1/2021	Sell	5,500	$118.48	$651,640.00	50,910
8/16/2021	Sell	5,500	$103.92	$571,560.00
6/14/2021	Sell	8,334	$131.44	$1,095,420.96	58,833
6/11/2021	Sell	8,333	$129.33	$1,077,706.89	58,833
5/10/2021	Sell	5,000	$110.43	$552,150.00	50,500
4/12/2021	Sell	5,000	$114.22	$571,100.00	50,500
3/10/2021	Sell	5,000	$118.48	$592,400.00	50,500
1/11/2021	Sell	5,000	$105.11	$525,550.00	49,072
12/10/2020	Sell	5,000	$94.82	$474,100.00	45,500
11/12/2020	Sell	30,000	$101.69	$3,050,700.00
10/12/2020	Sell	5,000	$78.67	$393,350.00	38,000
9/10/2020	Sell	5,000	$75.52	$377,600.00	38,000
6/16/2020	Sell	25,000	$94.41	$2,360,250.00	33,000
6/12/2020	Sell	8,333	$93.28	$777,302.24	33,000
6/1/2020	Sell	25,000	$90.64	$2,266,000.00	25,000
5/1/2020	Sell	25,000	$76.98	$1,924,500.00	25,000
4/1/2020	Sell	25,000	$64.37	$1,609,250.00	10,654

Andrew Craig Miller Buying and Selling Activity at Karuna Therapeutics

Karuna Therapeutics Company Overview

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $329.83

$329.83

50 Day Range

MA: $324.32

$313.97

$329.83

2 Week Range

Now: $329.83

$158.38

$329.99

Volume

5 shs

Average Volume

832,048 shs

Market Capitalization

$12.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Strange new buyer driving up gold

From Stansberry Research | Ad

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

Andrew Miller Biography and Net Worth

What is Andrew Craig Miller's net worth?

How old is Andrew Craig Miller?

What is Andrew Craig Miller's salary?

How do I contact Andrew Craig Miller?

Has Andrew Craig Miller been buying or selling shares of Karuna Therapeutics?

Who are Karuna Therapeutics' active insiders?

Are insiders buying or selling shares of Karuna Therapeutics?